In general, among the 91 USC patients in the present study, TP53 mutation was found in 88.2% (75/85), SEIC rate was 13.2% (12/91), the positive rate of ER was 52.2% (47/90), the positive rate of PR was 38.9% (35/90), lymph node metastasis rate was 34.5% (29/84), peritoneal cytology positive rate was 29.6% (21/71), and the LVSI rate was 47.8% (43/90). The gene discussed is TP53; the disease is metastatic malignant neoplasm in the lymph nodes.